Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Thoracic Malignancies
•
Medical Oncology
•
Thymoma and Thymic Carcinoma
How do you typically approach adjuvant therapy for a Masaoka stage IVa thymoma post-R0 resection?
Related Questions
For the neoadjuvant treatment for thymoma, when do you favor CAP with prednisone over CAP?
How do you prioritize treatment in a lung cancer patient who has HER2 IHC3+ along with other actionable mutations that have tumor-specific drugs available?
Would you consider using Elahere for patients with FOLR1-positive metastatic lung adenocarcinoma?
Would you change systemic therapy in a patient with SCLC with stable systemic disease but CNS progression?
Is DLL3 expression necessary for tarlatamab efficacy in small cell lung cancer?
Would you provide vitamin B12 supplementation to a patient on pemetrexed therapy if their B12 levels are normal or high?
How would you approach adjuvant therapy for patients with mucinous lung adenocarcinoma with an intestinal phenotype?
Does anyone have experience obtaining sunvozertinib in the second-line setting for patients with EGFR exon 20 insertion mutations?
Would you offer a RET inhibitor to a patient with de novo metastatic, RET V706M mutant squamous cell lung cancer?
For a patient with NSCLC harboring an EGFR or ALK mutation that transforms into SCLC, would you add immunotherapy to chemotherapy or avoid immunotherapy given the tumor's EGFR/ALK origin?
